Company
Hexagon
Novel ADC Payloads for Cancer
Also known as Hexagon Bio, Hexagon Bio, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Menlo Park, CA, United States
- Legal name
- Hexagon Bio, Inc.
- hexagonbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance to today’s payloads and expand ADC indications.
Funding snapshot
- Total raised
- $185MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series B, $77.3M2023-02-13
Funding rounds
- Series B
- $77.3M2023-02-13, Company stated
- Round, 2022
- $67.3M2022-09-30, SEC form D sold, 20 investors
- Round, 2021
- $61M2021-09-22, Company stated
- Round, 2021
- $61M2021-06-11, SEC form D sold, 14 investors
- Series A
- $47M2020-09-15, Company stated
- Round, 2018
- $12M2018-04-09, SEC form D sold, 12 investors
- Round, 2017
- $8.3M2017-06-16, SEC form D sold, 9 investors
Loading relationship preview